<DOC>
	<DOCNO>NCT01327261</DOCNO>
	<brief_summary>A group 24 healthy volunteer receive one tablet association levodopa 200 mg benserazide 50 mg correspond two drug product : test formulation ( Evoser ® ; Phoenix S.A.I.C . F. , Buenos Aires , Argentina ) reference formulation ( Madopar ® ; Roche Pharma , Switzerland ) ass relative bioavailability . After administration formulation 17 blood sample take levodopa measure HPLC . Pharmacokinetic parameter ( AUC , Tmax Cmax ) compare .</brief_summary>
	<brief_title>Fasting Comparative Bioavailability Two Tablet Formulations Levodopa /Benserazide Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Benserazide</mesh_term>
	<mesh_term>Levodopa</mesh_term>
	<criteria>Healthy Caucasian Argentinean male females volunteer age 21 50 year body mass index 19 27 kg/m2 enrol study . All volunteer provide write informed consent prior study initiation . History cardiovascular , hepatic , renal , psychiatric , neurologic , hematologic , metabolic disease Drug alcohol abuse within 2 year start study Smoking HIV , hepatitis B , hepatitis C infection Consumption prescribe overthecounter drug within 2 week study Participation similar study within past 6 month . Female subject pregnant , plan become pregnant , breastfeeding time study , require use effective method contraception ( intrauterine device hormonal method ) throughout study .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>levodopa</keyword>
	<keyword>benserazide</keyword>
	<keyword>bioequivalence</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>A Single - Dose</keyword>
	<keyword>Randomized- Sequence</keyword>
	<keyword>Open -Label Crossover Study</keyword>
</DOC>